Both auto-SCT and reduced intensity allo-SCT (RIST) are employed in the treatment of relapsed follicular lymphoma (FL). We have analysed the outcome of these two transplant procedures when used as a first transplant in this setting. We conducted a retrospective comparison of 726 patients who underwent an auto-SCT and 149 who underwent a RIST as a first transplant procedure for relapsed FL as reported to the Lymphoma Working Party of the European Bone Marrow Transplant. The non-relapse mortality (NRM) was significantly worse for patients undergoing a RIST (relative risk (RR) 4.0, Po0.001). The 1-year NRM was 15% for those undergoing a RIST compared with 3% for those undergoing an auto-SCT. Disease relapse or progression were significantly worse for those receiving an auto-SCT (RR 3.1, Po0.001). Patients undergoing a RIST had a 5-year relapse rate of 20% compared with 47% for those undergoing an auto-SCT. The PFS at 5 years was 57% for patients receiving a RIST compared with 48% for those receiving an auto-SCT. There was no significant difference in OS between the two groups. RIST is associated with a higher NRM and lower relapse rate in patients with relapsed FL.
INTRODUCTION
There is currently a wide range of therapeutic choices available for the treatment of patients with follicular lymphoma (FL) who relapse after first-line therapy. High-dose therapy and auto-SCT has been extensively used in the relapse setting, and there is evidence from a prospective study that it may be superior to conventional dose chemotherapy. 1 Auto-SCT is associated with acceptable toxicity and a low TRM, and long-term follow-up studies suggest that a significant minority of patients may be cured with these procedures. 2, 3 However, there are concerns about both late relapses and the development of secondary leukaemia following auto-SCT. [2] [3] [4] [5] Myeloablative therapy and allo-SCT has been employed in patients with advanced FL and is capable of inducing lasting remissions and cure even in patients with advanced disease. [6] [7] [8] However, this therapeutic modality has been limited in its application due to the high TRM and is generally reserved for younger patients. Reduced intensity allo-SCT (RIST) has been developed in an attempt to reduce the toxicity of allo-SCT and to extend the applicability of allo-SCT to older patients and those with co-morbidities. 9 ,10 Several groups have described promising outcomes in patients with advanced FL who have undergone a RIST. [11] [12] [13] [14] [15] However, the longer-term outcome of these procedures is not yet established, and there remain concerns regarding the toxicity of RIST.
Therefore, both auto-SCT and RIST may be considered as first SCT procedures for patients with relapsed FL, but there is currently a paucity of comparative data to guide clinicians as to which is the optimum approach. A prospective study addressing this question failed to recruit sufficient patients and was closed prematurely. 16 We have therefore conducted a retrospective analysis of the outcome of auto-SCT and RIST when performed as a first transplant procedure in patients with relapsed FL as reported to the European Bone Marrow Transplant (EBMT) registry.
consecutive patients to the lymphoma registry and are subject to on-site audits to assess data accuracy and consecutive reporting. All centres that had submitted Med-A forms for patients with FL undergoing either an auto-SCT or a RIST as a first transplant between 1998 and 2005 were invited to participate. Only patients with FL beyond first CR or PR reported as undergoing a first transplant procedure were included. Patients with transformed FL, those transplanted in first response or as part of a planned tandem transplant programme were excluded. In the RIST cohort, mismatched donors and cord blood transplants were excluded. There were 875 patients identified as being eligible for the study, 726 auto-SCT and 149 RIST patients. In multivariate analysis, there was no difference in outcomes when these patients were compared with patients excluded through lack of data (Med-A reports only). Informed consent was obtained locally according to regulations applicable at the time of transplantation. After 1 January 2003, all EBMT centres have been required to obtain written informed consent before data registration.
Study definitions
RIST was defined according to published EBMT criteria. 17 Status at transplantation was defined according to the EBMT definitions: CR was defined as the disappearance of tumour masses and diseaserelated symptoms; PR was considered when measurable lesions decreased by at least 50%; and relapse was defined as the occurrence of new sites of disease after a CR lasting for X3 months, whereas it was considered progression when CR had not been achieved. Monitoring of patients for relapse/progression post transplant was conducted according to individual centre's protocols. Relapse or progression (REL) were considered to be 'chemosensitive' if at least PR was achieved following the last course of chemotherapy, otherwise it was considered as 'chemoresistant'. OS was defined as the time from transplant to death from any cause. PFS was defined as the time from the day of transplantation until disease relapse/ progression or death from any cause. Non-relapse mortality (NRM) included all causes of death other than disease progression/relapse occurring at any time after transplant.
Good performance status was defined as Karnofsy score X80% or ECOG (Eastern Cooperative Oncology Group) score 0-1.
Statistical analysis
The primary objective of this study was to compare outcomes after RIST and auto-SCT for FL patients beyond first response, while adjusting for patient-, disease-and treatment-related variables. End points analyzed were NRM, REL, PFS and OS, as previously defined. Patient charactersitics were compared between groups using the Chi-square test or Fisher exact test for categorical variables and the t-test or Mann-Whitney U-test for continuous variables. The probabilities of PFS and OS were calculated from the time of transplantation using the Kaplan-Meier estimator and compared by the log-rank test. NRM and REL probabilities were generated using cumulative incidence estimates to account for competing risks. Comparisons of the two types of SCT and assessment of other potential risk factors for these four outcomes were performed using multivariate Cox proportional hazards regression analysis. The type of SCT was maintained in all steps of model building as the main factor of interest in this study. All variables were tested for a significant interaction with the main factor under study. The proportionality assumption of the Cox model was tested by adding a time-dependent covariate for each covariate factor. As the effect of the type of SCT on PFS outcome changed over time (nonproportional hazard), models were constructed to break the posttransplant time course into two periods (pre-and post-24 months after SCT). Cumulative incidences were calculated using the NCSS97 software (Number Cruncher Statistical System, Kaysville, UT, USA). All other computations were performed using the SPSS15.0 statistical package (SPSS Inc., Chicago, IL, USA). All P-values were two-sided.
RESULTS

Patient characteristics
Between January 1998 and December 2005, 726 patients undergoing an auto-SCT and 149 undergoing a RIST were identified who fulfilled the inclusion criteria. Patient-and disease-related characteristics are detailed in Table 1. NRM and GVHD There were 32 non-relapse deaths in the RIST group and 37 in the auto-SCT group. The median time to a transplant-related death was 6.1 (0.2-36) and 5.3 (0.2-93) months, respectively. The deaths in the RIST group were due to: GVHD, 3; infection, 15; GVHD and infection, 5; interstitial pneumonia, 3; and other causes, 6. In the auto-SCT group, the causes of NRM were: infection, 14; secondary malignancy, 3; organ failure, 2; and other causes, 18. The Conditioning regimen
Abbreviation: RIST ¼ reduced intensity allo-SCT.
Auto-SCT and RIC allo-SCT for follicular lymphoma SP Robinson et al cumulative incidences of NRM at 100 days, 1 and 3 years were 2, 3 and 5% in the auto-SCT group and 6, 17 and 22% in the RIST group ( Figure 1 ). In the multivariate analysis undergoing a RIST, age 450 years and refractory disease were the only factors associated with a significantly worse NRM ( (Figure 2 ). In the multivariate analysis, patients undergoing an auto-SCT, stage III ± IV disease at diagnosis, refractory disease at transplantation and poor PS at transplantation were associated with a significantly worse disease progression rate (Table 2) . When analysis was restricted to the RIST group, refractory disease (RR 2.8, CI 1.3-6.3, P ¼ 0.01) and more than three lines of previous therapy (RR 2.8, CI 1.1-6.9, P ¼ 0.03) were associated with a higher risk of disease REL. T-cell depletion had no impact on the relapse rate. Conversely, analysis restricted to the auto-SCT group identified refractory disease (RR 1. As the type of transplant did not satisfy the proportionality assumption, the impact of the type of SCT on PFS was investigated in two periods:o24 months after SCT and 424 months after SCT. The type of SCT was not associated with a different PFS in the first 24 months after SCT, whereas auto-SCT was associated with a significantly worse PFS in the later period.
relapse/progression rate was 31% while for patients with X3 risk factors the 5-year relapse/progression rate was 66%.
Management of post-transplant relapse
Of the 292 patients relapsing after an auto-SCT, 17 (6%) proceeded to a second autologous transplant and 56 (19%) to a RIST. Only 1 of the 29 (3%) patients relapsing in the RIST group received a second transplant (myeloablative allo-SCT). The remaining patients received either conventional chemotherapy or palliative care. For the 56 patients who underwent a RIST after a failed auto-SCT, the 3-year NRM, disease progression/relapse, PFS and OS rates were 30, 30, 39 and 50%, respectively.
PFS and OS
The median follow-up for surviving patients was 59 months (range 3-108) from transplant. The median follow-up in the auto-SCT and RIST groups was similar (59 and 60 months, respectively). The PFS at 1, 3 and 5 years was 77, 57 and 48% in the auto-SCT group and 68, 62 and 57% in the RIST group (Figure 3) . There was no significant difference in PFS between the two groups in the first 24 months post transplant. However, after 24 months there was a significant PFS advantage for those patients receiving a RIST ( Figure 3 and Table 2 ). Other factors predictive of improved PFS were age o50 years, disease stage I and II at diagnosis, chemosensitive disease at transplantation and good PS. The OS at 1, 3 and 5 years was 90, 78 and 72% in the auto-SCT group and 80, 68 and 67% in the RIST group, respectively (Figure 4) . In the multivariate analysis, there was no significant difference in the OS between those patients in the auto-SCT group and those in the RIST group. The only factors impacting on OS were age, disease status at transplant and performance status at transplant (Table 2) .
DISCUSSION
In the current study, we have sought to describe the outcome of auto-SCT and RIST when performed as a first transplant procedure in patients with relapsed FL. We have only included patients undergoing transplantation beyond first response, as this is the currently accepted indication for transplantation in FL. [18] [19] [20] A prospective study comparing auto-SCT with RIST in this setting unfortunately failed due to poor accrual, 16 and further prospective comparative studies in this setting are unlikely to be performed. Therefore, retrospective studies describing these two forms of transplant provide an important source of data. A major limitation of retrospective studies is the selection bias that may operate when SCT strategies are selected for patients. In the current study, patients undergoing an auto-SCT had different disease characteristics when compared with those undergoing a RIST. The two groups of patients also differed in the treatment used for relapse following the index transplant with substantially more patients in the auto-SCT group proceeding to a second SCT procedure. A further limitation of this study is the registry basis of the data, which may be of variable quality despite the use of on-site audits to assess accuracy and sequential reporting of transplants.
Despite these limitations, these data provide useful information describing the outcome of these two types of transplantation when used as a first transplant strategy for relapsed FL. It is clear that the toxicity associated with a RIST is significantly greater than that with an auto-SCT due largely to the high incidence of infectious complications and GVHD. Even with reduced intensity conditioning strategies, allo-SCT is associated with a significant NRM between 15% and 31%. [11] [12] [13] [14] [15] By contrast, auto-SCT is associated with a low early NRM of o5%. 2, 3, [18] [19] [20] Late toxicities must also be taken into consideration when selecting a transplant strategy. Thus following an auto-SCT the development of secondary MDS (myelodysplastic syndrome)/AML has been reported in up to 10% of patients at 10 years post transplant. 2, 4, 5, 21 The follow-up period of the current study was too short to identify all cases of secondary MDS/AML in the auto-SCT cohort and additional cases would be expected to occur with longer follow-up, thus negatively impacting on the outcome of this group. Conversely, GVHD remains a significant problem following a RIST with 50% of patients in this study developing cGVHD. Extensive cGVHD is a significant long-term complication of allogeneic transplantation that must be considered when choosing treatment options. Given that NRM remains a major problem post RIST, is it possible to identify a group of patients with a lower NRM following these procedures? The NRM following a RIST depended on three risk factors (age, disease status at transplant and donor source) and varied between 11% (no risk factors) and 35% (two or more risk factors) (data not shown). Further risk stratification of the NRM following a RIST may be possible using the comorbidity index described by Sorror, 22 which should be prospectively tested in this disease setting.
This study also demonstrates that the relapse rate following a RIST is lower than that following an auto-SCT, despite the patients in the RIST group having significantly more advanced and refractory disease at the time of the transplant. Studies comparing myeloablative allo-SCT with autologous transplantation have also demonstrated a lower relapse rate following an allograft. 7, 23, 24 The lower relapse rate following allo-SCT may be a consequence of either the graft versus lymphoma effect or the provision of stem cells that are uncontaminated by residual lymphoma. The existence of a GVL effect in FL has been demonstrated by the ability of DLIs to induce remissions in disease relapsing post allograft. [25] [26] [27] This study is not able to determine which of these mechanisms underlies the lower relapse rate, although both mechanisms are likely to be active. In this study, we were not able to demonstrate an impact of T-cell depletion on the relapse rate following an allo-SCT as suggested by others. 28 The apparent plateau in the relapse curve following a RIST is suggestive that these procedures may be curative for FL. 11 Recent data suggests that auto-SCT may also be curative for FL with 20-30% of patients achieving long-term disease-free survival. 2, 3 Longer-term follow-up of patients in both arms of this study will be required to confirm the respective chances of cure.
There was a PFS advantage for RIST in this study that became apparent at 2 years after transplantation. The lack of a benefit before this time point relates to the excess early NRM in the RIST group. However, if patients survive a RIST, their subsequent disease control would appear to be better than if subjected to an auto-SCT. Once patients relapsed after their transplant, the salvage therapy employed in the two groups was clearly different, with 25% of patients relapsing after an auto-SCT proceeding to a second transplant procedure while only 3% of patients relapsing after a RIST received a second transplant. This difference in salvage therapy employed represents a significant bias that confounds the comparison of the OS between the two groups and may partly explain the lack of difference in OS between the two groups. Given the transplant registry nature of this study, we are unable to better define the factors that determined the choice of therapy used for these relapsing cases.
Employing an auto-SCT in the first instance and reserving a RIST for patients who relapse after an auto-SCT represents an alternative strategy. Several investigators have demonstrated the feasibility and efficacy of this approach in a variety of haematological malignancies, 29 including FL. 30 In this study, 20% of patients relapsing after an auto-SCT proceeded to a RIST with a subsequent 3-year PFS of 39%, confirming that a RIST is an effective therapy in this setting. This strategy does, however, run the risk of the patient developing chemorefractory disease or significant comorbidities that may exclude the option of an allo-SCT. The development of novel transplant strategies combined with maintenance immunotherapy may further improve the efficacy of SCT therapy in FL. 31 These data confirm that both auto-SCT and RIST are effective treatments in the management of relapsed FL. The choice and timing of transplant must, however, be considered alongside alternative non-transplant strategies. First-line immunochemotherapy followed by maintenance Rituximab is emerging as the current standard of care. [32] [33] [34] Second-and third-line conventional regimens and emerging novel therapies may be effectively employed for relapsing FL and be combined with maintenance immunotherapy or radioimmunotherapy. [35] [36] [37] Although such conventional strategies are improving the overall prognosis in FL, there remain a significant number of patients who fail these therapies and for whom transplant strategies may be appropriate. In the absence of prospective clinical trials, the choice of treatment, transplant or non-transplant will need to be carefully selected for individual patients.
